Mutations in valosin-containing protein (VCP) cause a rare, autosomal dominant disease called inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD). One-third of patients with IBMPFD develop frontotemporal dementia, characterized by an extensive neurodegeneration in the frontal and temporal lobes. Neuropathologic hallmarks include nuclear and cytosolic inclusions positive to ubiquitin and transactive response DNA-binding protein 43 (TDP-43) in neurons and glial activation in affected regions. However, the pathogenic mechanisms by which mutant VCP triggers neurodegeneration remain unknown. Herein, we generated a mouse model selectively overexpressing a human mutant VCP in neurons to study pathogenic mechanisms of mutant VCPmediated neurodegeneration and cognitive impairment. The overexpression of VCP A232E mutation in forebrain regions produced significant progressive impairments of cognitive function, including deficits in spatial memory, object recognition, and fear conditioning. Although overexpressed or endogenous VCP did not seem to focally aggregate inside neurons, TDP-43 and ubiquitin accumulated with age in transgenic mouse brains. TDP-43 was also found to co-localize with stress granules in the cytosolic compartment. Together with the appearance of high-molecular-weight TDP-43 in cytosolic fractions, these findings demonstrate the mislocalization and accumulation of abnormal TDP-43 in the cytosol of transgenic mice, which likely lead to an increase in cellular stress and cognitive impairment. Taken together, these results highlight an important pathologic link between VCP and cognition. Valosin-containing protein (VCP), a member of the type II adenosine triphosphatase associated with diverse cellular activities superfamily, is ubiquitous and is highly abundant in all cell types, including neurons. 1e3 It forms a homohexameric structure and is involved in a variety of physiologic functions, including nuclear, endoplasmic reticulum, and Golgi membrane fusions; cell-cycle regulation; stress responseemediated apoptosis; B-and T-cell activation; transcriptional regulation; endoplasmic reticulumeassociated protein degradation; and autophagosome maturation. 4e9 Dysregulation of physiologic VCP function critically influences cell integrity and survival.
Mutations in VCP have been identified to cause a novel hereditary form of inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD). 10 More recently, VCP mutations have been identified in a subset population of patients with amyotrophic lateral sclerosis (ALS). 11 Therefore, VCP mutations are hypothesized to mediate as-yet-unknown mechanisms leading to skeletal muscle degeneration, bone deformation by osteoclast abnormality, and neurodegeneration. The penetrance of the disease phenotypes, however, varies among them. Approximately 30% of individuals with mutations develop frontotemporal dementia. 10, 12, 13 Pathologically, neurons develop vacuoles, inclusions, and buildup of ubiquitinated proteins and transactive response DNA-binding protein (TDP-43) in cytoplasmic and nuclear compartments. 14e16 No buildup of tau protein has been reported in patients, and the distribution of VCP seems unaltered in these neurons. 17 Although VCP is involved in various critical cellular activities, key pathogenic mechanisms altered by the diseaserelevant mutations are not well understood yet. To study the disease mechanisms and recapitulate the phenotypes, several in vivo models have been developed and reported. Recent studies by Taylor and colleagues 16 demonstrated that overexpression of a disease-specific mutant VCP causes degeneration in muscle, bone, and neurons in a transgenic (Tg) mouse model. Mice with mutant VCP exhibit clearance of TDP-43 from the nuclear compartment and buildup of cytoplasmic TDP-43 co-localizing with ubiquitin. 16 Similarly, Kimonis and colleagues 18 generated a knock-in mouse model of IBMPFD, which expresses a disease-relevant VCP mutation (R155H) at physiologically relevant levels. In this model, increased cytoplasmic ubiquitin deposits were also evident in neurons together with increased levels of TDP-43 in brain tissue. These recent findings strongly suggest that mutant VCP promotes pathologic proteinopathies in the brain.
Several mechanisms have been proposed to explain how mutant VCP exerts its detrimental effects on the brain. Using transfection on the neuroblastoma cell line SH-SY5Y, Gitcho et al 19 found that mutant VCP reduces proteasome activity and increases endoplasmic reticulum stress and apoptosis. Likewise, stable transfection of the activity-negative VCP mutant K524A leads to increased levels of the endoplasmic reticulum stress markers GRP78 and CHOP in differentiated PC12 cells. 20 Mutant VCP also promotes the accumulation of immature autophagic vesicles, suggesting that VCP is required for autophagosome maturation. 8 In this regard, protein levels of the autophagy marker LC3I/II have been reported to be increased in the brain as a consequence of mutations on VCP, 18 and it is well documented that mutant VCP produces impaired autophagy in muscle cells. 7, 21, 22 We sought to investigate the underlying molecular mechanisms of the IBMPFD-associated mutant VCP in neurons. We, therefore, generated a Tg mouse model overexpressing mutant human VCP under the control of Thy1.2 promoter (Thy-VCP) to achieve forebrain-specific transgene expression. These mice exhibit an age-dependent decline in cognition and neuronal accumulation of cytoplasmic TDP-43. We also found that TDP-43 deposits co-localize with ubiquitin and accumulate in stress granules in Tg mice. Highmolecular-weight TDP-43 was observed in the brain of mutant VCPeoverexpressing mice and was localized exclusively in the cytoplasm. This observation may provide clues to uncover key pathologic mechanisms of the disease and further validate the view that cytoplasmic TDP-43 accumulation is the culprit for mutant VCPeinduced neurodegeneration. Taken together, this Tg line provides an additional in vivo model to study the cellular and molecular mechanisms that drive neural degeneration associated with IBMPFD.
Materials and Methods

Generation of Tg Mice
Human wild-type VCP was purchased from OriGene Technologies Inc. (Rockville, MD), and a disease-relevant VCP A232E construct was generated by site-directed mutagenesis. The mutant VCP A232E was then amplified by PCR (Phusion PCR kit; Cell Signaling Technology, Beverly, MA) and subcloned into the Thy1.2 expression cassette 23 using a homologous recombination-based approach (In-Fusion system; Clontech Laboratories, Mountain View, CA). The sequence-verified Thy1.2-VCP A232E transgene was linearilized by NotI and PvuI, purified, and microinjected into the pronuclei of single-cell embryos harvested from C57BL/6J mice by the University of California at Irvine Transgenic Mouse Facility (Irvine, CA).
Southern Blot and PCR Analyses of the Thy-VCP A232E Transgene
All animal procedures and use were performed in strict accordance with NIH and University of California guidelines. All the mice used in this study were housed on a 12-hour light/dark schedule with ad libitum access to food and water. Tg mice were identified by tail DNA PCR genotyping and Southern blot analysis. For PCR genotyping, forward primer 5 0 -GAGGTATTCATCATGTGCT-3 0 and reverse primer 5 0 -AAGGACGATGCAAACAGCTT-3 0 ( Figure 1A ) liberated a 500-bp band from Tg mice ( Figure 1C ). Southern blot analysis was also performed to confirm the integrity of the transgene. Briefly, 2.5 kb of VCP cDNA was extracted by NheI and ClaI digestion and was used to make a probe for Southern blot analysis ( Figure 1A ). Ten micrograms of extracted tail DNA was digested overnight with EcoRI, NotI, and PvuI and was resolved overnight in 0.8% agarose gel. DNA was then denatured, transferred onto a nitrocellulose membrane, and probed with [P32]-CTP radiolabeled probe. The appearance of 4-and 5.5-kb bands on autoradiography indicated transgene-positive mice ( Figure 1B ).
Behavior Assays
Morris Water Maze The protocol was conducted as previously described. 24 Briefly, mice were trained to swim to a 14-cm-diameter circular Plexiglas platform submerged 1.5 cm beneath the surface of the water and invisible to the mouse while swimming. The platform was fixed in place, equidistant from the VCP A232E Abets TDP-43 Buildup in Neurons
The American Journal of Pathology -ajp.amjpathol.org 505 center of the tank and its walls. Mice were subjected to four training trials per day. During each trial, mice were placed into the tank at one of four designated start points in a pseudorandom order. Mice were trained for as many days as needed to reach the training criterion of 25 seconds (escape latency). If the mice failed to find the platform within 60 seconds, they were manually guided to the platform and were allowed to remain on it for 5 seconds. The probe was assessed 24 hours after the last training session and consisted of a 60-second trial without the platform. Escape latency on the probe trial was defined as the time taken by each animal to reach the area occupied by the platform during training. We also determined the number of times each animal completely crossed through the area occupied by the platform during training (platform crosses). Performance was monitored using the EthoVision XT version 7 video tracking software system (Noldus Information Technology Inc., Leesburg, VA). The numbers of mice used in the Morris water maze were as follows: 12 [6-month-old non-Tg (NT)], 12 (6-month-old A line), 11 (6-month-old B line), 12 (12-monthold NT), 10 (12-month-old A line), and 12 (12-month-old B line). These mice were also tested using the novel object recognition and contextual fear condition tests.
Novel Object Recognition
Each mouse was habituated to an empty Plexiglas arena (45 Â 25 Â 20 cm) for 3 consecutive days. On training (day 4), the mice were exposed to two identical objects placed at opposite ends of the arena for 5 minutes. Twenty-four hours later, the mice were allowed to explore one copy of the previously presented object (familiar) together with a new object for 5 minutes. A video camera was mounted above the arena, and all the sessions were recorded. Exploration was considered as pointing the head toward an object at a distance of <2.5 cm from the object, with its neck extended and vibrissae moving. Turning around, chewing, and sitting on the objects were not considered exploratory behaviors. The recognition index represents the percentage of the time that mice spend exploring the novel object. Mice that did not explore both objects during training were discarded from further analysis. Objects used in this task were carefully selected to prevent preference or phobic behaviors. To avoid olfactory cues, the objects were thoroughly cleaned with 70% ethanol and the sawdust was stirred after each trial.
Contextual Fear Conditioning
On training, mice were placed in the fear-conditioning chamber and were allowed to explore for 2 minutes before receiving three electric foot shocks (1 second, 0.2 mA; intershock interval, 2 minutes). Animals were returned to the home cage 30 seconds after the last foot shock. Twenty-four hours later, behavior in the conditioning chamber was video recorded for 5 minutes and subsequently was analyzed for freezing behavior, which was defined as the absence of all movement except for respiration.
Tissue Preparation
After deep anesthesia with sodium pentobarbital, the mice were perfused transcardially with 0.1 mol/L PBS, pH 7.4. Half the brain was fixed for 48 hours in PBS þ 4% paraformaldehyde and then was cryoprotected in PBS þ 30% sucrose for immunohistochemical and immunofluorescence analyses, and the other half was frozen in dry ice for biochemical analysis. Protein extracts were prepared by homogenizing whole brain hemisphere samples in 150 mg/mL of T-PER extraction buffer (Thermo Fisher Scientific Inc., Waltham, MA), complemented with protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO), and followed by centrifugation at 100,000 Â g for 1 hour. For nuclearcytoplasmic fractionation, tissue was processed using the NE-PER kit (Thermo Fisher Scientific Inc.) following the manufacturer's instructions. For alkaline phosphatase treatment, 60 mg of protein was incubated with 60 U of bovine alkaline phosphatase (Sigma-Aldrich) at 37 C for 1 hour. Protein concentration was determined using the Bradford assay (Bio-Rad Laboratories, Hercules, CA). Unless noted otherwise, all Tg samples were from B line animals.
Immunohistochemical Analysis
Coronal free-floating sections (25 to 40 mm) were pretreated with 3% H 2 O 2 /10% methanol in Tris-buffered saline (TBS) for 30 minutes. After TBS washes, sections were incubated once in TBS þ 0.1% Triton X-100 (TBST) for 15 minutes and once in TBST þ 3% bovine serum albumin (BSA; Sigma-Aldrich) for 30 minutes and were blocked for 1 hour in TBS þ 1% BSA þ 5% goat serum (Vector Laboratories, Burlingame, CA). Sections were incubated overnight with VCP primary antibody (dilution 1:2000) (MA3-004; Pierce Biotechnology, Rockford, IL) in TBS þ 1% BSA þ 2% goat serum at 4 C. After washes, sections were incubated with biotinylated anti-mouse secondary antibody in TBS þ 1% BSA þ 2% goat serum at room temperature for 1 hour (dilution 1:500; Vector Laboratories), followed by development using Vectastain ABC kit and diaminobenzidine reagents (Vector Laboratories). Sections were mounted on gelatin-coated slides, dehydrated in graded ethanol series, cleared with xylenes, and coverslipped with DPX mounting medium (BDH Laboratory Supplies, Poole, UK). The specificity of the immune reactions was controlled by omitting the primary antibody.
Immunofluorescence
Coronal free-floating sections (25 to 40 mm) were pretreated with sodium citrate, 50 mmol/L (pH 6.0), for 10 minutes at 95 C and then were allowed to cool for half an hour. After TBS washes, sections were incubated once in TBST for 15 minutes and once in TBST þ 3% BSA for 30 minutes and then were blocked for 1 hour in TBS þ 1% BSA þ 5% goat serum. Sections were incubated overnight with one or two ajp.amjpathol.org -The American Journal of Pathology of the following primary antibodies: antieTiA-1 (dilution 1:500) (ab2712; Abcam Inc., Cambridge, MA), TDP-43 (dilution 1:500) (12892-1-AP; Proteintech Group Inc., Chicago, IL), monoubiquitinated and polyubiquitinated proteins (dilution 1:500) (FK2; Enzo Life Sciences, Farmingdale, NY), PSD-95 (dilution 1:500) (ab18258; Abcam Inc.), and synaptophysin (dilution 1:200) (ab14692; Abcam Inc.) in TBS þ 1% BSA þ 2% goat serum at 4 C. After washes, sections were incubated with the appropriate secondary Alexa Fluoreconjugated antibody (dilution 1:200; Life Technologies Inc., Gaithersburg, MD) at room temperature for 1 hour, washed, and incubated with 300 nmol/L DAPI (Invitrogen, Carlsbad, CA) for 5 minutes. Sections were mounted onto gelatin-coated slides using Fluoromount-G (SouthernBiotech, Birmingham, AL) and were examined under an EVOS fl fluorescence microscope (Advanced Microscopy Group, Bothell, WA).
Semiquantitative analysis was performed using ImageJ software version 1.45s (NIH, Bethesda, MD). Nuclei were outlined and deleted from polyubiquitin or TiA-1 grayscale images; the rest was considered cytoplasmic staining. Images were converted to binary, and percentage of positive signal was computed from total image area. Three sections per animal were analyzed (5 to 6 mice per group).
For mean intensity measurements, three square regions of interest were defined on 16-bit grayscale images in the CA1 and CA3 regions, and mean pixel intensity was computed.
Immunoblotting
Equal amounts of protein were separated on 4% to 15% BisTris gel and were transferred to polyvinylidene difluoride membranes. Membranes were blocked for 1 hour in TBS þ 5% nonfat milk or Odyssey blocking solution (LI-COR Biosciences, Lincoln, NE). After blocking, membranes were incubated overnight with one or two of the following primary antibodies: TDP-43 (dilution 1:1000) (12892-1-AP; Proteintech Group Inc.), ubiquitin (dilution 1:3000) (Z0458; Dako, Carpinteria, CA), monoubiquitinated and polyubiquitinated proteins (dilution 1:1000) (FK2, Enzo Life Sciences), PSD-95 (dilution 1:1000) (ab18258; Abcam Inc.), synaptophysin (dilution 1:1000) (ab14692; Abcam Inc.), glyceraldehyde-3-phosphate dehydrogenase (dilution 1:5000) (FL-335; Santa Cruz Biotechnology, Santa Cruz, CA), p84 (dilution 1:1000) (5E10; Abcam Inc.), and tubulin (dilution 1:50,000) (B-5-1-2; Sigma-Aldrich) in TBS þ 5% nonfat milk or Odyssey blocking solution þ 0.2% Tween 20 at 4 C. After washes with TBS þ 0.1% Tween 20, membranes were incubated for 1 hour with the specific secondary antibodies at a dilution of 1:5000 (horseradish peroxidase conjugated; Pierce Biotechnology) or 1:15000 (IRDye; LI-COR Biosciences) in TBS þ 5% nonfat milk þ 0.2% Tween 20 þ 0.01% SDS. Blots were developed using SuperSignal (Thermo Fisher Scientific) or were scanned in an Odyssey infrared imager (LI-COR Biosciences). Image Studio software version 3.1.4 (LI-COR Biosciences) was used for protein quantification.
Sequential Extraction
Proteins from half the brain were extracted sequentially as described elsewhere. 25, 26 Briefly, brain tissue was first homogenized in low-salt (LS) buffer [10 mmol/L Tris, pH 7.5, 5 mmol/L EDTA, 1 mmol/L dithiothreitol, 10% sucrose, and protease/phosphatase inhibitor cocktails (Sigma-Aldrich)] and then was centrifuged at 25,000 Â g for 30 minutes at 4 C to collect the LS fraction. Pellets were washed with PBS and were homogenized in high-salt buffer (LS þ 1% Triton X-100 and 0.5 mol/L NaCl). The mixture was centrifuged at 180,000 Â g for 30 minutes at 4 C, and the high-salt fraction was collected. The resulting pellets were washed with PBS and were homogenized in sarkosyl buffer (LS þ 1% sarkosyl þ 0.5 mol/L NaCl). The mixture was incubated for 1 hour at 22 C with gentle shaking followed by centrifugation at 180,000 Â g for 30 minutes at 4 C. Sarkosyl-insoluble pellets were washed with PBS, resuspended in urea buffer (7 mol/L urea, 2 mol/L thiourea, 4% CHAPS, 30 mmol/L Tris, pH 8.5), and centrifuged at 25,000 Â g for 30 minutes at 22
C. The protein concentration of each fraction was quantified by the Bradford assay (Bio-Rad Laboratories). Samples were mixed with 4Â Laemmli loading buffer (Bio-Rad Laboratories) and 0.25 mol/L dithiothreitol, boiled for 10 minutes at 90 C, and loaded onto SDS gels as described previously herein.
Immunoprecipitation
Protein (150 mg) was precleaned for 1 hour with protein Geagarose (EMD Millipore Corporation, Billerica, MA) on a 360
rotator at 4 C. Beads were removed and samples were incubated with 1 mg of VCP antibody (MA3-004; Thermo Fisher Scientific) on a 360 rotator at 4 C. One hour later, protein Geagarose was added to samples and incubated for an additional 2 hours. Beads were washed several times, resuspended in 4Â Laemmli loading buffer (Bio-Rad Laboratories) þ 0.25 mol/L dithiothreitol, and boiled for 10 minutes. After centrifugation, supernatant was collected and analyzed by immunoblot.
SH-SY5Y Cell Transfection and Immunocytochemical Analysis
Cells were seeded at 70% confluency on chambered coverglass. Twenty-four hours later, 1 mg of one of the following constructs was transfected with BioT (Bioland Scientific, Paramount, CA) according to the manufacturer's instructions: human wild-type VCP, human VCP A232E , or human VCP R155H fused to enhanced green fluorescent protein. After 7 hours, the medium was replaced with fresh medium. Cells were processed for immunocytochemical analysis 72 hours after transfection. The VCPeenhanced green fluorescent protein plasmids used herein were a gift from Dr. Akira Kakizuka (Kyoto University, Kyoto, Japan).
For immunocytochemical analysis, cells were fixed in PBS þ 4% paraformaldehyde (pH 7.4) for 15 minutes. After
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The American Journal of Pathology -ajp.amjpathol.orgTBS washes, cells were incubated with TBST þ 3% BSA for 10 minutes and were blocked in TBS þ 1% BSA þ 5% goat serum for 1 hour. Cells were incubated overnight with TDP-43 primary antibody (dilution 1:500) (12892-1-AP, Proteintech Group Inc.) in TBS þ 1% BSA þ 2% goat serum at 4 C. After washes, sections were incubated with Alexa Fluoreconjugated anti-rabbit secondary antibody in TBS þ 1% BSA þ 2% goat serum at room temperature for 1 hour (dilution 1:200; Life Technologies Inc.), washed, and incubated with 300 nmol/L DAPI for 5 minutes. Cells were coverslipped with Fluoromount-G (SouthernBiotech) and were examined under an EVOS fl fluorescence microscope (Advanced Microscopy Group). Semiquantitative analysis was performed using ImageJ software. Ten areas of each coverslip were selected (three independent experiments per group), and nuclei were outlined and deleted from TDP-43 grayscale images. Images were converted to binary, and the granule size and number were calculated on green fluorescent proteinepositive cells.
Statistical Analysis
Comparisons between multiple groups used appropriate analysis of variance followed by Fisher post hoc tests. Comparisons between two groups used Student's t-test. P 0.05 was considered significant.
Results
Forebrain Overexpression of Mutant VCP Impairs Cognitive Function in an Age-Dependent Manner
Mutant VCP A232E eoverexpressing mice were generated by microinjection of Thy1.2-VCP A232E transgene into a single cell embryo from C57BL/6J mice. The Thy1.2 promoter limited expression of the transgene to forebrain neurons. 27 Three founder lines were isolated showing integration of the Thy-VCP A232E transgene. All the lines had the entire transgene successfully integrated into genomic DNA. The A line harbored the fewest copy numbers, whereas the B and C lines harbored approximately three to four times more copies of the transgene than the A line ( Figure 1B) . VCP expression was found to be higher on the brain of all Tg lines compared with their littermates (Figure 1D ). Detailed genetic studies indicated that the C line founder was mosaic; hence, we excluded this line from further analysis.
Because transgene expression was limited to forebrain neurons, and high expression was observed in the hippocampus and cortex (Supplemental Figure S1J) , a battery of behavioral tests, including the Morris water maze, novel object recognition, and contextual fear conditioning, was used to determine whether the expression of mutant VCP influences cognitive function in an age-and Tg dosedependent manner (Figure 2 ). In the Morris water maze, the higher VCP-expressing B line showed significant impairment in acquisition at 6 and 12 months of age, whereas impairment. Six-and 12-month-old mice were trained in hippocampal-and cortical-dependent behavioral tasks. A and B: The higher-expressing VCP A232E B line showed significant impairment in Morris water maze acquisition at 6 and 12 months of age, whereas the lower-expressing A line was not different from wild-type animals. C and D: Both 12-month-old Tg groups presented cognitive impairments when tested 24 hours later as measured by escape latency but not as measured by platform crosses. E: Both VCP A232E -expressing lines performed poorly in the object recognition task at 12 months of age but not at 6 months of age. y P < 0.05 from 50% (chance level, shown as a horizontal line). F: Only the higher-expressing B line showed impairments at 6 and 12 months of age when contextual fear conditioning was assessed (n Z 10 to 12 per group). *P < 0.05, **P < 0.01. Data are given as means AE SEM. ajp.amjpathol.org -The American Journal of Pathology the lower VCP-expressing A line was not different from age-matched wild-type mice (Figure 2, A and B) . However, both Tg lines were significantly impaired in memory retention, as measured by probe trial escape latency, at 12 months of age compared with NT mice ( Figure 2C ). The swim speed and swim distance in the defined timeframe were not different between age-matched NT and Thy-VCP A232E Tg mice (data not shown).
Similarly, object recognition showed that only 12-monthold Thy-VCP A232E mice (A and B lines) were significantly impaired in recalling the familiar object, but 6-month-old Tg mice were not different from chance level (50% recognition index), although NT mice were different ( Figure 2E ). In contextual fear conditioning, only the higher-expressing B line showed impairments at 6 and 12 months of age ( Figure 2F ). The overexpression of mutant VCP in the forebrain, therefore, mediated age-and dose-dependent cognitive impairment in mice.
Mutant VCP Abets Focal TDP-43 Deposits that Co-Localize with Stress Granules and/or Ubiquitin in the Cortex
The overexpression of mutant VCP did not cause alterations in the gross anatomy of the hippocampus and cortex, where transgene expression driven by the Thy1.2 promoter was maximal (data not shown). Also, we did not observe any apparent aggregation or abnormal accumulation of endogenous VCP in neurons in these regions in NT mouse brain (Supplemental Figure S1 , AeC). In Tg mice, however, VCP immunoreactivity was extended to dendrites in cortical and hippocampal regions, probably due to overexpression of mutant VCP (Supplemental Figure S1 , DeI). A lack of VCP aggregate consisted of histopathologic observations on patients with IBMPFD. 17 We next sought to examine whether TDP-43 immunoreactivity was altered in neurons. A previously reported Tg mouse model overexpressing mutant VCP exhibited complete clearance of TDP-43 from nuclear compartment and buildup of cytoplasmic TDP-43 deposits with ubiquitin. 16 In the present mouse model, we observed abnormal accumulations of TDP-43 only, although a small percentage (19%), in neurons of Thy-VCP A232E Tg mice but not in NT mice (Figure 3, C and  D) . Focal accumulation of TDP-43 was co-localized with stress granules, identified by TiA-1, in the cytoplasm (Figure 3, A and  B) . Quantification of 12-and 20-month-old cortical sections showed augmented levels of TiA-1 protein on 20-month-old Thy-VCP animals ( Figure 3I ). These findings support a redistribution of TDP-43 and increased stress responses, which may alter RNA metabolism and contribute to neurodegenerative processes. Similarly, a significantly increased number of Thy-VCP A232E neurons had ubiquitin cytosolic inclusions ( Figure 4, A and B) , which were co-localized with cytoplasmic Fluorescence microscopy analysis of 20-month-old mice revealed TiA-1 (red)epositive staining on wild-type (A) cortical sections but to a lesser degree than on VCP A232E (B). D: TiA-1 co-localized with TDP-43 (green) deposits in the cytoplasm of Tg brains but not NT (C). E and F: DAPI staining (blue) was used as nuclear marker. G and H: Merge images of NT (G) and Tg (H). I: Quantification of 12-and 20-month-old sections showed significant increases in TiA-1 levels on the latter age. Data are given as means AE SEM. Scale bars: 10 mm. n Z 5 to 6 per group. *P < 0.05. (Figure 4, D and H) . Accordingly, image analysis revealed that Thy-VCP A232E brains have more ubiquitin-positive staining ( Figure 4I ). Biochemical analyses demonstrated accumulation of ubiquitinated proteins in an age-dependent manner on Thy-VCP A232E mice ( Figure 4J) . Ubiquitinated protein accumulation was detected to be greater in Thy-VCP A232E brain cytoplasmic fractions (Figure 4 , K and L).
TDP-43 aggregates
TDP-43 Accumulates as a High-Molecular-Weight Form in the Thy-VCP A232E Mouse Model
The underlying mechanisms by which TDP-43 is abnormally redistributed into cytoplasm and gains cytotoxicity remain unknown. Recent studies have suggested that TDP-43 is posttranslationally modified and abnormally accumulates in cells. Phosphorylation, 28 ubiquitination, 25, 29 and proteolytic cleavage 30 of TDP-43 are found to associate with various disease states. We, therefore, sought to investigate whether particular forms of TDP-43 predominantly accumulate in the cytoplasm of Thy-VCP A232E Tg mice. We detected a highmolecular-weight (w90-kDa) TDP-43 band with greater intensity in aged B line Tg mice that corresponds to the size of dimeric TDP-43 ( Figure 5A ). Full-length TDP-43, on the other hand, was unchanged with age or transgene expression ( Figure 5A ). Nuclear-cytosolic fractionation showed a highmolecular-weight TDP-43 present only in the cytoplasm of Thy-VCP brain homogenates ( Figure 5, BeE) .
The aggregation states of TDP-43 were next determined by sequential extraction of brain tissue. We found several high-molecular-weight isoforms of TDP-43 in all fractions of Tg brain ( Figure 6, A and B) . A faint low-molecularweight TDP-43 band (25 to 30 kDa), previously described in patients with ALS and frontotemporal dementia, 25 was also detected in detergent-soluble and sarkosyl fractions ( Figure 6B ). In addition, we observed increased levels of high-molecular-weight ubiquitinated proteins in LS and urea fractions ( Figure 6C ).
Tg-Specific High-Molecular-Weight TDP-43 Interacts with VCP
The overexpression of mutant VCP induced aberrant inclusions and redistribution of TDP-43 in forebrain neurons (Figures 3, 4 , and 5). To determine whether VCP directly mediates these changes in TDP-43 through direct physical interaction, Thy-VCP A232E and NT brain samples were immunoprecipitated with a VCP antibody and then were immunoblotted for TDP- Figure 4 Thy-VCP A232E mice show age-dependent cytosolic accumulation of polyubiquitinated proteins. AeH: VCP A232E cortical sections from 20-month-old mice showed increased levels of polyubiquitin proteins (red) (B) and cytoplasmic TDP-43 (green) accumulation (D) compared with NT mice (A and C). E and F: DAPI staining (blue) was used as nuclear marker. G and H: Merge images of NT (G) and Tg (H). I: Quantification of 12-and 20-month-old sections uncovered increased levels of polyubiquitinated proteins on the Thy-VCP brain. J: Immunoblot analysis showed age-dependent buildup of polyubiquitinated proteins. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. K: Polyubiquitinated proteins were accumulated in the cytosolic compartment of mutant VCP mice. Tubulin was used as loading control. L: Quantification of K. Scale bars: 10 mm. n Z 5 to 6 per group. *P < 0.05, **P < 0.01. Data are given as means AE SEM. ajp.amjpathol.org -The American Journal of Pathology 43. We found that only high-molecular-weight TDP-43 was immunoprecipitated with VCP ( Figure 7A ).
To determine whether high-molecular-weight TDP-43 is a hyperphosphorylated isoform, Tg and NT brain samples were treated with alkaline phosphatase and were analyzed by Western blot. Alkaline phosphatase treatment did not reduce high-molecular-weight TDP-43 levels ( Figure 7, B and C) . Together, these data suggest a physical interaction between VCP and a high-molecular-weight TDP-43 isoform in Tg mice.
Mutant VCP Overexpression Does Not Show Evident Neurodegeneration
As shown in Figure 2 , forebrain neuron-specific expression of mutant VCP exhibited age-and dose-dependent cognitive impairment in mice. We sought to investigate whether loss of synapses contributed to cognitive impairment in Thy-VCP A232E Tg mice. Both synaptophysin and PSD-95 in the hippocampus were quantitatively measured by immunoblots (Supplemental Figure S2 , A and B, for synaptophysin and Supplemental Figure S2 , C and D, for PSD-95), but no definitive differences were detected. Similarly, immunofluorescence staining failed to show any statistical significance in the intensity of synpaptophysin (Supplemental Figure S2 , E and F) or PSD-95 (Supplemental Figure S2 , G and H) in VCP Tg mice compared with age-matched NT mice.
It has been proposed that mutant VCP leads to increased NF-kB signaling, producing degeneration of muscle and bone tissue through hyperactivity of the NF-kB pathway. 16, 31 VCP modulates the NF-kB signaling cascade by regulating the degradation of IkB-a, which, in turn, frees NF-kB from an inactive to a phosphorylated active conformation that translocates to the nucleus. In this regard, it was shown that myoblast C2C12 cells overexpressing mutant VCP present lower IkB-a protein levels and increased phosphorylated NF-kB protein levels compared with cells overexpressing wild-type VCP when stimulated with tumor necrosis factor a. 16 To address whether altered NF-kB signaling underlies cognitive impairment in Thy-VCP A232E mice, we analyzed NF-kB and IkB protein levels in the nuclear and cytoplasmic fractions of wild-type and Tg animals (Supplemental Figure S3 , AeE) and the activity of NF-kB by electrophoretic mobility shift assay (Supplemental Figure S3F ), but we did not uncover differences between genotypes (Supplemental Figure S3) . However, we observed that a small number of neurons exhibited nuclear localization of NF-kB in VCP Tg mice (Supplemental Figure S3G) . Further studies are required to identify the link between VCP, TDP-43, and cognitive impairment in the brain.
SH-SY5Y Cells Transfected with Mutant VCP Present TDP-43 Cytoplasmic Inclusions
To evaluate VCP-mediated TDP-43 accumulation in the cytoplasm in a cell culture model, human neuroblastoma Discussion TDP-43 is a DNA-and RNA-binding protein and a component of heterogeneous nuclear ribonucleoproteins, which are involved in RNA transcription, splicing, and transport. 32, 33 In particular, because TDP-43 has nuclear localizing signal and nuclear export signal in its sequence along with two DNA/ RNA recognition motifs (RRM1 and RRM2), 34 it is critically involved in the trafficking of mRNAs between the nucleus and cytosol. 35, 36 Although TDP-43 is predominantly localized in the nuclear compartment, its physiologic role in spines and involvement in synaptic plasticity have recently been reported, 35 further suggesting a diverse role of TDP-43 in neurons. Shortly after abnormal TDP-43 was first recognized as forming a part of cytosolic inclusions in affected neurons in ALS and frontotemporal dementia, 25 mutations on TDP-43 causing ALS were identified, 37, 38 confirming that TDP-43 plays a critical and causal role in the pathogenesis of ALS.
Redistribution and accumulation of TDP-43 in the cytosol are also observed in affected skeletal muscle fibers in inclusion body myositis, 14 suggesting that TDP-43 may be a primary culprit in various human diseases in multiple tissues. In some cases, TDP-43 is reported to co-localize with ubiquitin or stress granules. 39e41 In Tg mice and cell culture models, increased cytosolic accumulation of TDP-43 or its proteolytic 25-kDa fragment triggers neurotoxicity. 42, 43 However, detailed molecular mechanisms by which cytosolic TDP-43 induces cell death have not yet been defined.
Some biochemical evidence suggests that TDP-43 forms a homodimer in physiologic conditions. 34 In addition, structural analysis of the TDP-43 RRM2 domain showed similar structural arrangement to heterogeneous nuclear ribonucleoprotein A1 protein, which forms a homodimer when bound to DNA. 34 In this study, it was also revealed that dimeric RRM2 is quite resistant to temperature because of a highly stable antiparallel b-sheet conformation, presenting a denaturing temperature of approximately 85 C. On the other hand, a TDP-43 fragment that included both RRM domains of TDP-43 protein showed a much lower melting point (approximately 50 C). In the present report, we observed a high-molecular-weight TDP-43 that is consistent with the size of dimeric TDP-43, exclusively expressed in the cytoplasm of Tg mice. This putative dimeric TDP-43 band would also be in a thermal-stable conformation, as well as resistant to denaturing and reducing conditions ( Figure 5 ). In this regard, Shiina et al 44 reported an 86-kDa cytoplasmic TDP-43 isoform in several human cell lines. The 86-kDa band reacts to specific N-terminal and C-terminal TDP-43 antibodies and is sensitive to siRNA targeted to TDP-43. Moreover, samples treated with dithiothreitol or 2-mercaptoethanol before immunoblotting showed the 86-kDa band when immunoblotted with TDP-43 antibodies. These authors detected a similar molecularweight band in detergent-soluble brain samples from patients with disparate affections, including ALS, parkinsonism, multiple sclerosis, schizophrenia, and depression. 44 When this 86-kDa isoform was overexpressed in cell culture, it promoted the accumulation of TDP-43ereactive proteins that range in size from 70 to 200 kDa, indicating that dimeric TDP-43 would be a seed molecule for TDP-43 inclusions. 44 VCP is involved in multiple cellular functions through interaction with a plethora of cofactors. For example, VCP associates with several E3 ligases to deliver polyubiquitinated proteins to the proteasome for degradation. 45, 46 In addition, several polyubiquitinated proteins require direct interaction with the N-terminal region of VCP to translocate to the proteasome. 47 Accordingly, mutant VCP isoforms lead to altered proteasome activity and induce apoptosis. 17, 19 A previous report showed interaction between VCP and TDP-43 in ALS brain samples and SHSY-5Y cells transfected with mutant VCP. 19 Herein, we observed interaction between VCP and TDP-43 in the Thy-VCP mouse; however, VCP coupled exclusively to the putative TDP-43 homodimer, probably to direct it to the proteasome for degradation, but when this process is disrupted by mutant VCP, TDP-43 accumulates in the cytoplasm. In support of this view, it has been reported that IBMPFD-relevant VCP mutations cause cytoplasmic TDP-43 inclusions in vitro. 19 Furthermore, some evidence indicates that TDP-43 is degraded through the ubiquitin-proteasome system and that impairment of the proteasome leads to aggregation of ubiquitinated TDP-43 in the cytoplasm. 19, 48, 49 Herein, we observed VCP A232E -mediated accumulation of TDP-43 in the cytoplasm specifically concentrated in stress granules. In response to stress insults, cells sequester nonessential RNA transcripts in proteinmRNA complexes called stress granules, allowing available resources to deal with stress. Protein-mRNA complex formation relies on regulated aggregation of RNA-binding proteins, such as TDP-43. 50 In this regard, it has been shown that cellular stress produces TDP-43 recruitment to stress granules 40, 41 and that TDP-43 is involved in stress granule assembly and maintenance. 51 Consistently, TDP-43 regulates the maturation of stress granules containing G3BP and co-localizes with stress granules containing TiA-1. 51, 52 These pieces of evidence indicate that regulated protein aggregation of TDP-43, similar to other RNA-binding proteins, exerts direct influence on stress granule dynamics and the way cells deal with stress. 50 In physiologic conditions, stress granules rapidly dissociate when stress is overcome. However, mutations on key proteins of the stress granules pathway and/or chronic stress may lead to up-regulation of stress granule formation and, consequently, pathologic aggregation of proteins. 50 Accordingly, ALS-relevant TDP-43 mutations have been reported to produce larger stress granules than their wild-type counterpart, 41,53 which may be an indication of an altered stress response or an increased propensity for aggregation. It has also been shown that TDP-43 accumulation in stress granules can progress to stable cytosolic aggregates that may be part of a toxic gain-offunction process. 54 Therefore, manipulation of the pathways involved in stress granule formation provides an opportunity to modify the pathologic protein aggregation commonly observed in neurodegenerative diseases. 50 Another interesting and related mechanism by which TDP-43 may contribute to pathologic abnormality is derived from the fact that TDP-43 is required for activity-dependent transport and stability of mRNAs in dendrites. 35 Pathologic TDP-43 relocalization to stress granules may impair local dendritic mRNA translation in response to neuronal activity, contributing to neurodegeneration through the disruption of normal synaptic function.
We generated a Tg mouse overexpressing an IBMPFDassociated mutant VCP selectively in forebrain neurons to investigate the molecular and cellular mechanisms by which mutant VCP mediates neuronal dysfunction and neurodegeneration. Although extensive neurodegeneration was not observed throughout the life span of mice, age-dependent cognitive decline, increased stress response, and altered TDP-43 distribution in affected brain regions were clearly detected in Thy-VCP A232E mice. Previous Tg models have successfully recapitulated different IBMPFD phenotypes, contributing valuable insights on IBMPFD disease mechanisms. 15, 16, 18, 42, 55 The present Tg mouse model exhibited several remarkable changes in affected neurons, including accumulation of high-molecular-weight TDP-43 only in the cytosolic compartment with age. This model could serve as an additional in vivo tool to further study the brain abnormalities associated with IBMPFD and other TDP-43 proteinopathies without confounding complications, such as myopathy and bone deformations, that could interfere with cognitive assessments. ajp.amjpathol.org -The American Journal of Pathology
